The Effectiveness of a 5% Retinoic Acid Peel Combined with Microdermabrasion for Facial Photoaging: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Background. Tretinoin has been shown to improve photoaged skin. This study was designed to evaluate the efficacy and tolerability of a 5% retinoic acid peel combined with microdermabrasion for facial photoaging. Materials and Methods. Forty-five patients, aged 35–70, affected by moderate-to-severe photodamage were enrolled in this trial. All patients received 3 sessions of full facial microdermabrasion and 3 sessions of either 5% retinoic acid peel or placebo after the microdermabrasion. Efficacy was measured using the Glogau scale. Patients were assessed at 2 weeks and 1, 2, and 6 months after treatment initiation. Results. The mean ± SD age of participants was 49.55±11.61 years, and the majorities (73.3%) were female. Between 1 month and 2 months, participants reported slight but statistically significant improvements for all parameters (P<0.001). In terms of adverse effects, there were statistically significant differences reported between the 5% retinoic acid peel groups and the control group (P<0.001). The majority of adverse effects reported in the study were described as mild and transient. Conclusion. This study demonstrated that 5% retinoic acid peel cream combined with microdermabrasion was safe and effective in the treatment of photoaging in the Iranian population. This trial is registered with IRCT2015121112782N8.

Download Full-text

A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy

Lasers in Surgery and Medicine ◽

10.1002/lsm.22682 ◽

2017 ◽

Vol 49 (8) ◽

pp. 738-742 ◽

Cited By ~ 4

Author(s):

Monique J. Vanaman Wilson ◽

Isabela T Jones ◽

Douglas C. Wu ◽

Mitchel P. Goldman

Keyword(s):

Clinical Trial ◽

Photodynamic Therapy ◽

Adverse Effects ◽

Aminolevulinic Acid ◽

Controlled Clinical Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing the Effects of Angelica Gigas Nakai Extract on Blood Triglycerides

Nutrients ◽

10.3390/nu12020377 ◽

2020 ◽

Vol 12 (2) ◽

pp. 377

Author(s):

Su-Jin Jung ◽

Woo-Rim Kim ◽

Mi-Ra Oh ◽

Youn-Soo Cha ◽

Byung-Hyun Park ◽

...

Keyword(s):

Clinical Trial ◽

Placebo Group ◽

Density Lipoprotein ◽

Atherogenic Index ◽

Control Group ◽

Controlled Clinical Trial ◽

Double Blind ◽

Angelica Gigas ◽

Double Blind Placebo ◽

Angelica Gigas Nakai

Angelica gigas Nakai, Korean dang-gui, has long been widely used in traditional treatment methods. There have been a number of studies of the health effects of A. gigas and related compounds, but studies addressing effects on blood triglycerides (TG) are lacking. To investigate the effects of A. gigas Nakai extract (AGNE) on TG in Korean subjects, we carried out a 12-week, randomized, double-blind, placebo-controlled clinical trial. Subjects who met the inclusion criterion (130 mg/dL ≤ fasting blood TG ≤ 200 mg/dL) were recruited for this study. One hundred subjects were assigned to the AGNE group (n = 50) or the placebo group (n = 50), who were given 1 g/day of AGNE (as a gigas Nakai extract 200 mg/d) in capsules and the control group for 12 weeks. Outcomes were efficacy TG, lipid profiles, atherogenic index, and safety parameters were assessed initially for a baseline measurement and after 12 weeks. After 12 weeks of supplementation, TG and very low-density lipoprotein cholesterol (VLDL-C) concentration and TG/HDL-C ratio in the AGNE group were significantly reduced compared to the placebo group (p < 05). No significant changes in any safety parameter were observed. These results suggest that the ingestion of AGNE may improve TG and be useful to manage or prevent hypertriglyceridemia.

Download Full-text

Efficacy of Maternal Choline Supplementation During Pregnancy in Mitigating Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Alcoholism Clinical and Experimental Research ◽

10.1111/acer.13769 ◽

2018 ◽

Vol 42 (7) ◽

pp. 1327-1341 ◽

Cited By ~ 31

Author(s):

Sandra W. Jacobson ◽

R. Colin Carter ◽

Christopher D. Molteno ◽

Mark E. Stanton ◽

Jane S. Herbert ◽

...

Keyword(s):

Clinical Trial ◽

Cognitive Function ◽

Adverse Effects ◽

Prenatal Alcohol Exposure ◽

Alcohol Exposure ◽

Controlled Clinical Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Prenatal Alcohol

Download Full-text

Analgesic and antisympathetic effects of clonidine in burn patients, a randomized, double-blind, placebo-controlled clinical trial

Indian Journal of Plastic Surgery ◽

10.1055/s-0039-1699176 ◽

2007 ◽

Vol 40 (01) ◽

pp. 29-33

Author(s):

Ostadalipour Abbas ◽

Jamshidi Mojgan ◽

Zamani Alieh ◽

Jamshidi Maryam ◽

Ashrafi Tavasoli Ahmad

Keyword(s):

Blood Pressure ◽

Clinical Trial ◽

Systolic Blood Pressure ◽

Control Group ◽

Controlled Clinical Trial ◽

Case Group ◽

Burn Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Oral Clonidine

ABSTRACT Objectives:Unlike most other Analgesic drugs, α2 adrenoceptor agonists are capable of producing analgesia. The aim of this study was to evaluate the Analgesic and antisympathetic effects of clonidine, an α2 adrenoceptor agonist in burn patients.Materials and Methods:This randomized, double-blind, placebo-controlled clinical trial performed on one hundred burn patients in Zarea Hospital, Mazandaran, Iran from august 2004 to July 2005. All patients divided in two groups. Case group (n=50) received oral clonidine, 3.3μg/kg TDS and controls (n=50) received placebo. Heart rate and systolic blood pressure and pain severity Visual analogue score (VAS), were recorded after clonidine administration. Statistical analysis was done by means of Mann Witney U test. Results:50 patients (mean age 28.96±10 years) in case group, and 50 patients (mean age 27.60±11.4 years) in control group were studied. VAS pain scores and heart rate in the clonidine group were significantly lower than the control group (P< 0.0001, P< 0.02).there were no significant difference in systolic blood pressure between the two groups on the first and second day but on third day the systolic blood pressure in clonidine group, was lower than controls significantly (P=0.002). Conclusion: This study demonstrates that the use of oral clonidine affects the hemodynamic response to pain in burn patients. Our study demonstrated that clonidine can produce good analgesia and decreased in sympathetic over activity in burn patients, and also reduce opioid dose requirements.

Download Full-text

Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial Assessing the Effect of Fructooligosaccharides in Infants with Constipation

Nutrients ◽

10.3390/nu10111602 ◽

2018 ◽

Vol 10 (11) ◽

pp. 1602 ◽

Cited By ~ 3

Author(s):

Daniela Souza ◽

Soraia Tahan ◽

Thabata Weber ◽

Humberto Araujo-Filho ◽

Mauro de Morais

Keyword(s):

Clinical Trial ◽

Transit Time ◽

Statistical Significance ◽

Control Group ◽

Controlled Clinical Trial ◽

First Year ◽

Therapeutic Success ◽

Double Blind ◽

Double Blind Placebo ◽

First Year Of Life

Constipation often begins in the first year of life. The aim of this study was to assess the effect of fructooligosaccharides (FOS) in the treatment of infants with constipation. This randomized, double-blind, placebo-controlled clinical trial included infants with constipation who were randomly assigned to one of two parallel groups: FOS or placebo. Either the FOS supplement or the placebo was added to the infant formula. Thirty-six infants completed the 4-week intervention. Therapeutic success occurred in 83.3% of the FOS group infants and in 55.6% of the control group infants (p = 0.073; one-tailed test). Compared with the control group, the FOS group exhibited a higher frequency of softer stools (p = 0.035) and fewer episodes of straining and/or difficulty passing stools (p = 0.041). At the end of the intervention, the mouth-to-anus transit time was shorter (22.4 and 24.5 h, p = 0.035), and the Bifidobacterium sp. count was higher (p = 0.006) in the FOS group. In conclusion, the use of FOS in infants with constipation was associated with significant improvement in symptoms, but the results showed no statistical significance regarding the success of the therapy compared with the control group. FOS was associated with reduced bowel transit time and higher counts of the genus Bifidobacterium in the stool.

Download Full-text

Intravenous Tenoxicam for Analgesia following Laparoscopic Cholecystectomy

Anaesthesia and Intensive Care ◽

10.1177/0310057x9802600108 ◽

1998 ◽

Vol 26 (1) ◽

pp. 56-60 ◽

Cited By ~ 15

Author(s):

F. J. Munro ◽

S. J. Young ◽

I. J. Broome ◽

H. M. Robb ◽

G. J. Wardall

Keyword(s):

Clinical Trial ◽

Laparoscopic Cholecystectomy ◽

Placebo Group ◽

Adverse Effects ◽

Controlled Clinical Trial ◽

Patient Controlled Analgesia ◽

Double Blind ◽

Rescue Analgesia ◽

Double Blind Placebo ◽

Pain Scores

In a double-blind, placebo-controlled clinical trial (power of 80% to detect a 30% reduction in morphine consumption, P<0.05) we have determined that intraoperative intravenous administration of tenoxicam 40 mg during laparoscopic cholecystectomy, when compared with placebo, was associated with a significant reduction in consumption of morphine at 6 hours and 12 hours (P<0.05) but not at 24 hours, when assessed by patient-controlled analgesia. Furthermore there was a significantly greater requirement for “rescue” analgesia with intramuscular morphine in the placebo group during the period of the study. There was no difference between the groups in pain scores, either at rest or on movement, nor in the incidence of nausea and vomiting. No patient in either group suffered a respiratory rate less than 8/min or oversedation at any time, and there were no other adverse effects.

Download Full-text

Therapeutic effectiveness of Lishi Oral Liquid combined with levocetirizine in treating atopic dermatitis: A randomized double-blind placebo-controlled clinical trial

Traditional Medicine and Modern Medicine ◽

10.1142/s2575900019500162 ◽

2019 ◽

Vol 02 (04) ◽

pp. 179-183

Author(s):

Jingxiu Chai ◽

Jie Ren ◽

Kexiang Yan ◽

Feng Xu ◽

Ying Ma ◽

...

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Life Quality ◽

Chinese Herbs ◽

Control Group ◽

Controlled Clinical Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Oral Liquid ◽

And Control

Objective: To observe the efficacy and safety of Lishi Oral Liquid (LOL), a Chinese herbs formula, combined with levocetirizine, an antihistamine drug, in patients with damp-heat atopic dermatitis (AD). Methods: A randomized double-blind placebo-controlled clinical trial was conducted. Ninety patients diagnosed with damp-heat atopic dermatitis were randomly assigned to Lishi Oral Liquid group and control group at the ratio of 1:1. Patients were given one Lishi Oral Liquid or placebo three times per day. Both groups were treated with allantoin and vitamin E cream by topical use and levocetirizine by oral administration. Patients were followed up at the second and fourth week. The primary outcome was the scoring of atopic dermatitis (SCORAD). The secondary outcomes were visual analogue scale (VAS) and dermatology life quality index (DLQI). Results: After two weeks of treatment, there were statistical differences in SCORAD between these two groups ([Formula: see text]), whereas VAS and DLQI showed no statistical differences. There were significant differences in SCORAD and VAS between two groups at the end of four weeks of treatment ([Formula: see text]). However, no significant differences were observed in DLQI after four weeks of treatment. No serious adverse event was found during this clinical trial. Conclusion: LOL combined with levocetirizine is effective and safe for damp-heat AD treatment.

Download Full-text